Cargando…

Disease-, region- and cell type specific diversity of α-synuclein carboxy terminal truncations in synucleinopathies

Synucleinopathies, including Parkinson’s disease (PD), Lewy body dementia (LBD), Alzheimer’s disease with amygdala restricted Lewy bodies (AD/ALB), and multiple system atrophy (MSA) comprise a spectrum of neurodegenerative disorders characterized by the presence of distinct pathological α-synuclein...

Descripción completa

Detalles Bibliográficos
Autores principales: Hass, Ethan W., Sorrentino, Zachary A., Xia, Yuxing, Lloyd, Grace M., Trojanowski, John Q., Prokop, Stefan, Giasson, Benoit I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403399/
https://www.ncbi.nlm.nih.gov/pubmed/34454615
http://dx.doi.org/10.1186/s40478-021-01242-2
_version_ 1783745992250621952
author Hass, Ethan W.
Sorrentino, Zachary A.
Xia, Yuxing
Lloyd, Grace M.
Trojanowski, John Q.
Prokop, Stefan
Giasson, Benoit I.
author_facet Hass, Ethan W.
Sorrentino, Zachary A.
Xia, Yuxing
Lloyd, Grace M.
Trojanowski, John Q.
Prokop, Stefan
Giasson, Benoit I.
author_sort Hass, Ethan W.
collection PubMed
description Synucleinopathies, including Parkinson’s disease (PD), Lewy body dementia (LBD), Alzheimer’s disease with amygdala restricted Lewy bodies (AD/ALB), and multiple system atrophy (MSA) comprise a spectrum of neurodegenerative disorders characterized by the presence of distinct pathological α-synuclein (αSyn) inclusions. Experimental and pathological studies support the notion that αSyn aggregates contribute to cellular demise and dysfunction with disease progression associated with a prion-like spread of αSyn aggregates via conformational templating. The initiating event(s) and factors that contribute to diverse forms of synucleinopathies remain poorly understood. A major post-translational modification of αSyn associated with pathological inclusions is a diverse array of specific truncations within the carboxy terminal region. While these modifications have been shown experimentally to induce and promote αSyn aggregation, little is known about their disease-, region- and cell type specific distribution. To this end, we generated a series of monoclonal antibodies specific to neo-epitopes in αSyn truncated after residues 103, 115, 119, 122, 125, and 129. Immunocytochemical investigations using these new tools revealed striking differences in the αSyn truncation pattern between different synucleinopathies, brain regions and specific cellular populations. In LBD, neuronal inclusions in the substantia nigra and amygdala were positive for αSyn cleaved after residues 103, 119, 122, and 125, but not 115. In contrast, in the same patients' brain αSyn cleaved at residue 115, as well as 103, 119 and 122 were abundant in the dorsal motor nucleus of the vagus. In patients with AD/ALB, these modifications were only weakly or not detected in amygdala αSyn inclusions. αSyn truncated at residues 103, 115, 119, and 125 was readily present in MSA glial cytoplasmic inclusions, but 122 cleaved αSyn was only weakly or not present. Conversely, MSA neuronal pathology in the pontine nuclei was strongly reactive to the αSyn x-122 neo-epitope but did not display any reactivity for αSyn 103 cleavage. These studies demonstrate significant disease-, region- and cell type specific differences in carboxy terminal αSyn processing associated with pathological inclusions that likely contributes to their distinct strain-like prion properties and promotes the diversity displayed in the degrees of these insidious diseases. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-021-01242-2.
format Online
Article
Text
id pubmed-8403399
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84033992021-08-30 Disease-, region- and cell type specific diversity of α-synuclein carboxy terminal truncations in synucleinopathies Hass, Ethan W. Sorrentino, Zachary A. Xia, Yuxing Lloyd, Grace M. Trojanowski, John Q. Prokop, Stefan Giasson, Benoit I. Acta Neuropathol Commun Research Synucleinopathies, including Parkinson’s disease (PD), Lewy body dementia (LBD), Alzheimer’s disease with amygdala restricted Lewy bodies (AD/ALB), and multiple system atrophy (MSA) comprise a spectrum of neurodegenerative disorders characterized by the presence of distinct pathological α-synuclein (αSyn) inclusions. Experimental and pathological studies support the notion that αSyn aggregates contribute to cellular demise and dysfunction with disease progression associated with a prion-like spread of αSyn aggregates via conformational templating. The initiating event(s) and factors that contribute to diverse forms of synucleinopathies remain poorly understood. A major post-translational modification of αSyn associated with pathological inclusions is a diverse array of specific truncations within the carboxy terminal region. While these modifications have been shown experimentally to induce and promote αSyn aggregation, little is known about their disease-, region- and cell type specific distribution. To this end, we generated a series of monoclonal antibodies specific to neo-epitopes in αSyn truncated after residues 103, 115, 119, 122, 125, and 129. Immunocytochemical investigations using these new tools revealed striking differences in the αSyn truncation pattern between different synucleinopathies, brain regions and specific cellular populations. In LBD, neuronal inclusions in the substantia nigra and amygdala were positive for αSyn cleaved after residues 103, 119, 122, and 125, but not 115. In contrast, in the same patients' brain αSyn cleaved at residue 115, as well as 103, 119 and 122 were abundant in the dorsal motor nucleus of the vagus. In patients with AD/ALB, these modifications were only weakly or not detected in amygdala αSyn inclusions. αSyn truncated at residues 103, 115, 119, and 125 was readily present in MSA glial cytoplasmic inclusions, but 122 cleaved αSyn was only weakly or not present. Conversely, MSA neuronal pathology in the pontine nuclei was strongly reactive to the αSyn x-122 neo-epitope but did not display any reactivity for αSyn 103 cleavage. These studies demonstrate significant disease-, region- and cell type specific differences in carboxy terminal αSyn processing associated with pathological inclusions that likely contributes to their distinct strain-like prion properties and promotes the diversity displayed in the degrees of these insidious diseases. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-021-01242-2. BioMed Central 2021-08-28 /pmc/articles/PMC8403399/ /pubmed/34454615 http://dx.doi.org/10.1186/s40478-021-01242-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Hass, Ethan W.
Sorrentino, Zachary A.
Xia, Yuxing
Lloyd, Grace M.
Trojanowski, John Q.
Prokop, Stefan
Giasson, Benoit I.
Disease-, region- and cell type specific diversity of α-synuclein carboxy terminal truncations in synucleinopathies
title Disease-, region- and cell type specific diversity of α-synuclein carboxy terminal truncations in synucleinopathies
title_full Disease-, region- and cell type specific diversity of α-synuclein carboxy terminal truncations in synucleinopathies
title_fullStr Disease-, region- and cell type specific diversity of α-synuclein carboxy terminal truncations in synucleinopathies
title_full_unstemmed Disease-, region- and cell type specific diversity of α-synuclein carboxy terminal truncations in synucleinopathies
title_short Disease-, region- and cell type specific diversity of α-synuclein carboxy terminal truncations in synucleinopathies
title_sort disease-, region- and cell type specific diversity of α-synuclein carboxy terminal truncations in synucleinopathies
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403399/
https://www.ncbi.nlm.nih.gov/pubmed/34454615
http://dx.doi.org/10.1186/s40478-021-01242-2
work_keys_str_mv AT hassethanw diseaseregionandcelltypespecificdiversityofasynucleincarboxyterminaltruncationsinsynucleinopathies
AT sorrentinozacharya diseaseregionandcelltypespecificdiversityofasynucleincarboxyterminaltruncationsinsynucleinopathies
AT xiayuxing diseaseregionandcelltypespecificdiversityofasynucleincarboxyterminaltruncationsinsynucleinopathies
AT lloydgracem diseaseregionandcelltypespecificdiversityofasynucleincarboxyterminaltruncationsinsynucleinopathies
AT trojanowskijohnq diseaseregionandcelltypespecificdiversityofasynucleincarboxyterminaltruncationsinsynucleinopathies
AT prokopstefan diseaseregionandcelltypespecificdiversityofasynucleincarboxyterminaltruncationsinsynucleinopathies
AT giassonbenoiti diseaseregionandcelltypespecificdiversityofasynucleincarboxyterminaltruncationsinsynucleinopathies